Buehlmann



GanglioCombi-Light

… the expert’s choice: for basic screening

test

GanglioCombi-Light includes frequent gangliosides such as GD1b, GQ1b and GM1. Patients may be analysed for antibodies against each of these gangliosides so to obtain an IgG and IgM “mini-profile” per patient.

 

 

 

A Microtiter plate of GanglioCombi-Light is coated as follows:

Fig 1a

As an example, a GanglioCombi-Light could be used as shown in Fig 1b. Doing an IgG and IgM profile per patient there is capacity for 12 patients per plate.

Fig 1b

anti-GM1 antibodies: anti-IgG GM1 antibodies are implicated in the pathogenesis of Guillain-Barré Syndrome (GBS) and anti-IgM GM1 antibodies in multifocal neuropathy (MMN) and motor neuron diseases (MND). anti-IgM GM1 antibodies may be present as monoclonal IgM paraprotein or as a polyclonal IgM. Polyclonal IgG may be detected in patients with motor neuropathies. High GM1 antibody titers may be detected in association with in Guillain-Barré Syndrome (GBS) following Campylobacter jejuni infection. The fact that GM1 is the only common Glycolipid antigen reactive with all of the GM1 antibodies found in motor nerve disorders suggests that it is the relevant target antigen in neural tissue.

Anti-GD1b antibodies: Reactivity against Gangliosides containing disialosyl groups, particularly GD1b, has been reported in isolated cases of acute and chronic idiopathic ataxic neuropathies (SAN).
The clinical picture comprises a chronic neuropathy with marked sensory ataxia and areflexia and with relatively preserved motor function in the limbs. In addition many patients have preserved motor function. When present in their entirety, these clinical features are described under the acronym CANOMAD (chronic, ataxic, neuropathy, opthalmoplegia, IgM paraprotein, cold agglutinins, disialosy antibodies).

Anti-GQ1b antibodies: Anti- IgG GQ1b antibodies are closely associated with Miller-Fisher syndrome (MFS), which is discussed to be a variant of Guillain-Barré syndrome. Up to 100% of MFS patients have these antibodies. Anti-GQ1b antibodies decay rapidly with clinical recovery and usually are not found in normal and disease control samples. The close serologic-clinical association make anti-GQ1b antibodies in suspected cases of MFS a useful diagnostic marker for physicians with therapeutic significance.
 

Product Information

GanglioCOMBI-LIGHT

Method

ELISA

Time to results

4.5 h

Sample Type

20 µl serum (1:50)

Standard range

quantitative

Isotypes

IgG and gM

Order code

EK-GCL-GM 2x12 profiles
CE

DOWNLOADS

Instruction
for use* GanglioCombi-Light

Instruction
for use* GanglioCombi-Light-GM

Technical Information

English  

[PDF 0.3MB] [PDF 0.3MB]

Deutsch

Francais

Italiano

* Multilingual document [EN, DE, FR, IT, ES]

Contact

BÜHLMANN Laboratories AG
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch

Distributors
Order
About us
Job opportunities

News

Calprotectin ELISA Automation

BÜHLMANN has set a focus on automation of its ELISA tests, starting with Calprotectin. A number of validated protocols are available on the commonly use  more

Interviews from Dr. Christoph Noppen (Viollier, Allschwil) about the EGFR test from EntroGen and from Dr. Günter Dollenmaier (ZLMSG) about the Anyplex II RV16 test from Seegene

Please read the two new success stories with our new products. You will find the interview with Dr. Christoph Noppen about the evaluation of the EGFR Rea  more

Interviews on calprotectin by BÜHLMANN on the National Health channel UK

TV programme on calprotectin diagnosis for IBD and BÜHLMANN Laboratories on the NHS National Health Channel in the UK. The interviews are scheduled to be  more

BÜHLMANN releases a new calprotectin test

CALcheck Blue™ is a rapid qualitative screening test. Easy to use, with Quick Prep extraction, no pipetting, no vortexing , reaction time of 10 minutes to  more

Get our RSS - Feed